AG
VRTX icon

AIA Group’s Vertex Pharmaceuticals VRTX Stock Holding History

AIA Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Buy
31,601
+2,079
+7% +$921K 0.2% 70
2026
Q1 		$13.2M Sell
29,522
-4,299
-13% -$2M 0.19% 77
2025
Q4 		$15.3M Sell
33,821
-22,233
-40% -$9.58M 0.23% 60
2025
Q3 		$22M Buy
56,054
+11,570
+26% +$4.84M 0.39% 36
2025
Q2 		$19.8M Buy
44,484
+10,255
+30% +$4.73M 0.43% 38
2025
Q1 		$16.6M Buy
34,229
+4,314
+14% +$2.01M 0.41% 41
2024
Q4 		$12M Sell
29,915
-871
-3% -$404K 0.29% 48
2024
Q3 		$14.3M Buy
30,786
+1,522
+5% +$731K 0.37% 41
2024
Q2 		$13.7M Buy
29,264
+4,898
+20% +$2.13M 0.4% 39
2024
Q1 		$10.2M Buy
24,366
+5,766
+31% +$2.44M 0.33% 39
2023
Q4 		$7.57M Buy
18,600
+1,512
+9% +$559K 0.31% 43
2023
Q3 		$5.94M Buy
17,088
+314
+2% +$110K 0.29% 44
2023
Q2 		$5.9M Buy
16,774
+8,977
+115% +$3.02M 0.29% 43
2023
Q1 		$2.46M Buy
7,797
+89
+1% +$26.7K 0.13% 64
2022
Q4 		$2.23M Sell
7,708
-1,925
-20% -$587K 0.14% 66
2022
Q3 		$2.79M Sell
9,633
-1,893
-16% -$545K 0.18% 52
2022
Q2 		$3.25M Sell
11,526
-955
-8% -$256K 0.17% 55
2022
Q1 		$3.26M Buy
12,481
+9,397
+305% +$2.23M 0.14% 63
2021
Q4 		$677K Sell
3,084
-2,981
-49% -$580K 0.03% 159
2021
Q3 		$1.1M Buy
+6,065
New +$1.18M 0.06% 137
2021
Q1 		– Sell
-1,767
Closed -$373K – 212
2020
Q4 		$373K Buy
+1,767
New +$405K 0.04% 142

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AIA Group's VRTX Position: Q2 2026 in Review

AIA Group increased its Vertex Pharmaceuticals (VRTX) stake by 7% in Q2 2026, buying an estimated $921K and bringing the position to 31,601 shares worth $15.7M. The position accounts for 0.2% of the portfolio, ranked #70.

AIA Group first reported a position in VRTX in Q4 2020 and has held it in 21 quarters since. The position peaked at $22M in Q3 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • AIA Group held 31,601 shares of Vertex Pharmaceuticals worth $15.7M as of Q2 2026.
  • AIA Group bought 2,079 Vertex Pharmaceuticals shares in Q2 2026, an estimated $921K.
  • Vertex Pharmaceuticals made up 0.2% of AIA Group's portfolio in Q2 2026, its #70 holding.
  • AIA Group first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • AIA Group's Vertex Pharmaceuticals position peaked at $22M in Q3 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on AIA Group's 13F filing for Q2 2026, filed 31 Jul 2026.